Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 88

When launched in 2004, Genentech's Avastin^® was one of the most expensive drugs on the market, with a US$4400 monthly price tag.

Indication: Breast, colorectal, kidney, non‐small‐cell lung, glioblastoma, ovarian cancers

Manufacturer: Roche

Global Sales in 2017: US$7.1 billion

Generic name: Bevacizumab

Launch date: 2004